A key national pro-life group has accused the U.S. Department of Justice of undermining Louisiana’s efforts to roll back the Biden administration’s eased restrictions on mifepristone when it asked a court to pause the Pelican State’s challenge to that policy.
The Food and Drug Administration recently approved a new generic form of mifepristone – a pill commonly, but not exclusively, used for early abortion – drawing criticism from pro-life advocates. It marks the second time a Trump administration has approved a generic form of the pill.
Louisiana lawmakers are considering legislation that would classify the abortion-inducing drugs mifepristone and misoprostol as controlled dangerous substances, meaning that possession of these drugs without a prescription could lead to fines or jail time.
In response to the upcoming Supreme Court case about access to the commonly used abortion pill, mifepristone, the U.S. bishops are calling on Catholics across the country to pray for an end to abortion.
The Supreme Court said it will hear arguments on March 26 about how patients can access the commonly used abortion pill, mifepristone.
The Supreme Court agreed Dec. 13 to look at a dispute over the availability of a commonly used abortion pill, mifepristone, making it the first abortion case it will hear since its decision overturning Roe v. Wade last year.
The number of legal abortions provided by virtual-only clinics via abortion pill prescriptions spiked 72% in the year following the Supreme Court’s reversal of Roe v. Wade, according to a report by #WeCount, a research project by the Society of Family Planning, a group that supports legal abortion.
Chemical abortion in the form of the “abortion pill” now accounts for 54% of U.S. abortions in 2022, up from 39% in 2017, according to the Guttmacher Institute, a research organization with historical ties to Planned Parenthood, the nation’s largest abortion provider.
In a two-hour hearing on May 17 looking at the U.S. Food and Drug Administration’s decades-old approval of an abortion pill, federal judges seemed to have a harsher line of questioning for attorneys for the federal government and the drug maker, indicating they might be sympathetic to those challenging the drug’s availability.
A federal appeals court in Louisiana is hearing arguments May 17 about the accessibility of the abortion drug mifepristone.
